Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
about
Multiple endocrine neoplasia type 2Activation of 5-HT4 receptors facilitates neurogenesis of injured enteric neurons at an anastomosis in the lower gutThyroid cancer: current molecular perspectives.Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancersDasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.BAY 43-9006 inhibition of oncogenic RET mutants.Pre-clinical and clinical significance of heparanase in Ewing's sarcoma.Proteomic Identification of DNA-PK Involvement within the RET Signaling Pathway.PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell CarcinomaRET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.RET TKI: potential role in thyroid cancers.The role of cell lines in the study of neuroendocrine tumors.Sorafenib and thyroid cancer.Thyroid Cancer: Role of RET and Beyond.Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.Effects of glial cell line-derived neurotrophic factor on dental pulp cells.RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.Medullary thyroid carcinoma relapse reversed with dichloroacetate: A case report.Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models.Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.A protein tyrosine kinase receptor, c-RET signaling pathway contributes to the enteric neurogenesis induced by a 5-HT4 receptor agonist at an anastomosis after transection of the gut in rodents.Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis
P2860
Q21203027-9BB20A0A-9546-493A-843B-962B7101BDBDQ26776453-2CC5A30E-89D3-4361-854A-1D75EC3FADE6Q33760910-6FC352D5-5649-49A3-8D8B-E998A0FA4604Q34078370-C3E45277-4FF7-40E6-97EB-A04FBA068117Q34123724-101456FC-AE2A-4C64-8D1D-C3EDB9A996BFQ34258443-44B68BE0-050D-4D98-9C5A-BD5EBE6516CEQ34565246-B1983499-7DF3-4544-B33A-D787C3073618Q34664539-85061703-606D-41FC-B42C-D451A20D87C1Q35660873-B37DAC0B-766C-4DD4-B09E-64F8E92DA169Q35832219-0CEDCF31-D61E-4CE7-B7EF-4F6A002C2315Q36764627-EAD895FE-5450-4E13-AB07-291938AB34EDQ37134454-28F030A6-E94D-44FE-8891-E56F122F591BQ37403891-D9C9AE58-69ED-409C-A6AD-42D6BB2F092DQ37565298-B7979DB6-3148-42B6-B1A6-696EAEA4ADC3Q37580294-650D20BD-A05B-4BAD-B630-C0B7AA01EB30Q37979656-F9C31773-9D91-48DA-A220-21B6E736E416Q38005913-513857C0-9EF2-44DE-B343-98EED11E111EQ38118647-EDAB33EA-B1FD-43C4-9CF8-70A80E9EC24CQ38208316-4C60002E-369E-4939-ABE8-1FF92E8E09CFQ38425184-A08996B6-9D3A-4E5B-8C30-7E1D1E0E5B5CQ39017645-AA5BE08C-6B92-4968-8C56-708AA7BAD1F4Q39025184-FFAD096E-25C7-437A-B020-F64B5A26C505Q39038767-9C553FF8-FD34-4A85-BB6E-1A54B1F555F0Q39492719-D2314CEB-8819-4E8B-A1A8-D1EE3B04FC40Q39901958-DE6A7290-9BF7-4D35-83F6-12BB5F4624F0Q42026891-BB6F379A-B5C4-4203-ABD6-40FD3FA6A341Q45866246-D268D853-FFB4-4976-89D3-ED5D2ABBB897Q49010203-9BBB7139-3D1D-4C0F-8EEE-BE7AFC9A5CF8Q50085302-2A28E424-1A5C-4E61-89A4-75698271AD0EQ54279337-FE6FC310-E9EB-4D55-9B45-627C9720AC8AQ58053853-A05ECD49-42EA-4E3D-8A2F-1D5C2E51618E
P2860
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Cellular effects and antitumor ...... d medullary thyroid carcinoma.
@en
Cellular effects and antitumor ...... d medullary thyroid carcinoma.
@nl
type
label
Cellular effects and antitumor ...... d medullary thyroid carcinoma.
@en
Cellular effects and antitumor ...... d medullary thyroid carcinoma.
@nl
prefLabel
Cellular effects and antitumor ...... d medullary thyroid carcinoma.
@en
Cellular effects and antitumor ...... d medullary thyroid carcinoma.
@nl
P2093
P2860
P356
P1476
Cellular effects and antitumor ...... d medullary thyroid carcinoma.
@en
P2093
Antonia Martinetti
Chiara Zanchi
Cinzia Lanzi
Diletta Laccabue
Ettore Seregni
Franco Zunino
Giovanna Petrangolini
Giuditta Cuccuru
Giuliana Cassinelli
Graziella Pratesi
P2860
P304
P356
10.1093/JNCI/DJH184
P407
P577
2004-07-01T00:00:00Z